Glenmark Pharmaceuticals announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Goa, India with a Voluntary Action Indicated (VAI) status.

The inspection was conducted at the Company's manufacturing facility from 22 June 2026 to 30 June 2026.